Welcome to our dedicated page for Fresenius news (Ticker: FSNUY), a resource for investors and traders seeking the latest updates and insights on Fresenius stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fresenius's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fresenius's position in the market.
Fresenius Kabi (FSNUY) and AABB announced the 21st annual Blood Collectors Week, to be held September 6–12, 2026, across the United States. The recognition week honors blood collection professionals such as phlebotomists, apheresis operators, recruiters, technicians, drivers, and medical directors. Nearly 200 blood collection facilities are expected to participate through recognition events, social media engagement, and employee appreciation activities. Resources, participating centers and engagement tools are available at bloodcollectors.org and via the @bloodcollectors account on X.
Fresenius Kabi (FSNUY) announced the U.S. launch of FDA‑approved generic Sugammadex Injection in a Simplist® ready‑to‑administer prefilled syringe on September 3, 2026. The product is initially offered as a 200 mg per 2 mL single‑dose syringe for operating room use.
Sugammadex Injection is indicated to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. The Simplist® format requires no assembly at the point of care, supporting streamlined medication management and reducing steps where errors can occur.
The company states that Sugammadex products are formulated, filled, and packaged in the United States to enhance domestic manufacturing and supply‑chain resiliency. Products are available for ordering immediately, with detailed prescribing and safety information provided in the official labeling.
Fresenius (OTC: FSNUY) has launched Fresenius Ventures, a corporate venture capital fund designed to invest in healthcare founders, technologies, and business models from early to growth stages. The unit combines capital with medical, regulatory, and operational expertise and offers access to clinical, scientific, and academic networks.
According to Fresenius, the fund plans to invest more than €200 million over the next five years, focusing on fields adjacent to its (Bio)Pharma, MedTech, and Care Provision platforms, including precision nutrition, microbiome research, new modalities, and digital care solutions. The fund is led by Dr. Thomas Michael Thestrup, formerly of Angelini Ventures, who brings over 15 years of healthcare and venture experience. Fresenius reported €22.6 billion in revenue in 2025 and operates in more than 60 countries.